Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PNP | P00491 | 14/20 | 0.55 |
| ▸ | MTAP | Q13126 | 5/20 | 0.54 |
| ▸ | HPRT1 | P00492 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL505864 | 0.88 | MTAP (0.60) | PNPMTAPHPRT1 | |
| Hydrochloric Acid SCHEMBL4834005 | 0.86 | MTAP (0.62) | PNPMTAPHPRT1 | |
| SCHEMBL7100238 | 0.81 | PNP (0.60) | PNPMTAPHPRT1 | |
| SCHEMBL506019 | 0.81 | PNP (0.60) | PNPMTAPHPRT1 | |
| SCHEMBL5606739 | 0.81 | PNP (0.60) | PNPMTAPHPRT1 | |
| SCHEMBL506459 | 0.81 | MTAP (0.72) | PNPMTAP | |
| Hydrochloric Acid SCHEMBL4841325 | 0.80 | MTAP (0.74) | PNPMTAP | |
| SCHEMBL4840335 | 0.78 | HPRT1 (0.48) | PNPMTAPHPRT1 | |
| SCHEMBL505494 | 0.76 | MTAP (0.45) | PNPMTAPHPRT1 | |
| SCHEMBL14509058 | 0.75 | PNP (0.65) | PNPMTAPHPRT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1023308-B1 | INHIBITORS OF NUCLEOSIDE METABOLISM | EINSTEIN COLL MED (US) | 2005-09-07 | — | — | EP | claimed |
| US-6660719-B2 | Inhibiting T-Cell proliferation | BIOCRYST PHARMACEUTICALS INC. | 2003-12-09 | — | — | US | claimed |
| US-20030114466-A1 | Inhibiting T-cell proliferation | BIOCRYST PHARMACEUTICALS, INC. | 2003-06-19 | — | — | US | claimed |
| US-20030096830-A1 | Inhibitors of nucleoside metabolism | BIOCRYST PHARMACEUTICALS, INC. | 2003-05-22 | — | — | US | claimed |
| US-20020061898-A1 | Inhibitors of nucleoside metabolism | BIOCRYST PHARMACEUTICALS, INC. | 2002-05-23 | — | — | US | claimed |
| US-20170216272-A1 | COMPOSITIONS FOR TREATING OR PREVENTING OBESITY AND INSULIN RESISTANCE DISORDERS | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2017-08-03 | — | — | US | disclosed |
| US-9597347-B2 | Compositions for treating obesity and insulin resistance disorders | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2017-03-21 | — | — | US | disclosed |
| EP-3031461-A1 | COMPOSITIONS FOR TREATING OR PREVENTING OBESITY AND INSULIN RESISTANCE DISORDERS | The President and Fellows of Harvard College (US) | 2016-06-15 | — | — | EP | disclosed |
| US-9241916-B2 | Cognitive performance with sirtuin activators | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2016-01-26 | — | — | US | disclosed |
| US-20150133396-A1 | COMPOSITIONS FOR TREATING OR PREVENTING OBESITY AND INSULIN RESISTANCE DISORDERS | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2015-05-14 | — | — | US | disclosed |
| US-8846724-B2 | Compositions for treating obesity and insulin resistance disorders | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2014-09-30 | — | — | US | disclosed |
| US-8242171-B2 | Method for reducing the weight of a subject or inhibiting weight gain in a subject | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2012-08-14 | — | — | US | disclosed |
| US-6660719-B2 | Inhibiting T-Cell proliferation | BIOCRYST PHARMACEUTICALS INC. | 2003-12-09 | — | — | US | disclosed |
| US-20030114466-A1 | Inhibiting T-cell proliferation | BIOCRYST PHARMACEUTICALS, INC. | 2003-06-19 | — | — | US | disclosed |
| US-20030096830-A1 | Inhibitors of nucleoside metabolism | BIOCRYST PHARMACEUTICALS, INC. | 2003-05-22 | — | — | US | disclosed |
| US-6492347-B2 | TREATMENT AND/OR PROPHYLAXIS OF INFECTION CAUSED BY PROTOZOAN PARASITE BY ADMINISTERING COMPOUND TO INHIBIT PURINE NUCLEOSIDE HYDROLASE, PURINE NUCLEOSIDE PHOSPHORYLASE, AND/OR PURINE PHOSPHORIBOSYL TRANSFERASE | ALBERT EINSTEIN COLLEGE OF MEDICINE OF YESHIVA UNIVERSITY | 2002-12-10 | — | — | US | disclosed |
| US-20020061898-A1 | Inhibitors of nucleoside metabolism | BIOCRYST PHARMACEUTICALS, INC. | 2002-05-23 | — | — | US | disclosed |
| US-6228847-B1 | ADMINISTERING PYRROLO(3,2-D)PYRIMIDINE DERIVATIVES AS PURINE NUCLEOSIDE PHOSPHORYLASE INHIBITOR | ALBERT EINSTEIN COLLEGE OF MEDICINE | 2001-05-08 | — | — | US | disclosed |
| US-6066722-A | Inhibitors of nucleoside metabolism | ALBERT EINSTEIN COLLEGE OF MEDICINE OF YESHIVA UNIVERSITY (US) | 2000-05-23 | — | — | US | disclosed |
| US-5985848-A | EFFECTIVE INHIBITORS OF PURINE NUCLEOSIDE PHOSPHORYLASE AND/OR NUCLEOSIDE HYDROLASES; TREATMENT AND/OR PROPHYLAXIS OF A PROTOZOAN INFECTION | ALBERT EINSTEIN COLLEGE OF MEDICINE OF YESHIVA UNIVERSITY (US) | 1999-11-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150133396-A1 | COMPOSITIONS FOR TREATING OR PREVENTING OBESITY AND INSULIN RESISTANCE DISORDERS | FABP4, GPR119, SIRT1 | PNP 3921/4885MTAP 3429/4885HPRT1 4585/4885 |
| US-20020061898-A1 | Inhibitors of nucleoside metabolism | PNP, APRT, NUDT14 | PNP 1/4885MTAP 34/4885HPRT1 6/4885 |
| US-20030114466-A1 | Inhibiting T-cell proliferation | PNP, TYMP, ENTPD5 | PNP 1/4885MTAP 7/4885HPRT1 40/4885 |
| US-20170216272-A1 | COMPOSITIONS FOR TREATING OR PREVENTING OBESITY AND INSULIN RESISTANCE DISORDERS | FABP4, GPR119, SIRT1 | PNP 3921/4885MTAP 3429/4885HPRT1 4585/4885 |
| US-20030096830-A1 | Inhibitors of nucleoside metabolism | CFH, NADK, UGT1A3 | PNP 35/4885MTAP 1036/4885HPRT1 114/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.